

Recombinant RAVN virus (RAVV) Glycoprotein minus the Mucin Domain (rGPΔmuc)

Catalog #: 0513-015

Lot #: 1804001


Description: Recombinant, purified RAVV rGP Δ muc protein with Strep-Tag® is produced in stably-transfected Drosophila Schneider 2 (S2) cells and is purified by FPLC. Within the species Marburg marburgvirus contains two virus types, Marburg virus (MARV) and RAVV viruses. RAVV is a close relative of the much more commonly known MARV.

Storage: -80°C

Size: $100 \mu g/vial$ is supplied in PBS, pH 7.4 (supplemented with arginine, glutamic acid, and glycerol) at a concentration of $1.247 \mu g/mL$. The theoretical molecular weight of the protein is $56 \mu c$

Relevance: Recombinant glycoprotein provides a means for antibody development, control protein for testing, and a tool to enhance research.

Related Products: IBT provides a wide array of anti-filovirus specific antibodies and other infectious disease reagents. Please see our website, <u>www.ibtbioservices.com</u> for more details.



(Panel A) SDS-PAGE demonstrating 1 μg and 5 μg (lane 1, 2 respectively) of RAVV rGP Δ muc protein under denaturing and reducing conditions. MW denotes Novex® Sharp pre-stained protein standard.

(Panel B and C) Western blot detection of RAVV rGP Δ muc at 50 ng, 100 ng and 500 ng (lanes 1-3) under denaturing and reducing conditions. (B) RAVV rGP Δ muc was detected using IBT's rabbit anti-MARV GP2 polyclonal antibody (cat# 0303-007) at 0.5 μ g/mL and anti-rabbit IgG-HRP conjugate, followed by TMB membrane substrate. (C) RAVV rGP Δ muc was detected using IBT's anti-MARV GP1 monoclonal antibody at 0.5 μ g/mL and anti-mouse IgG-HRP conjugate, followed by TMB membrane substrate.

ELISA Data

RAVV rGPAmuc ng/well	OD 650 nm
800.000	3.575
400.000	3.509
200.000	3.415
100.000	3.228
50.000	3.084
25.000	2.803
12.500	2.429
6.250	1.915
3.125	1.416
1.563	0.911
0.781	0.529
0.391	0.298

Plate was coated with RAVV rGP Δ muc starting at 800 ng/well, serially diluted in DPBS. The washed plate was detected using one dilution of a positive control serum, followed with anti-IgG-HRP conjugate and TMB microwell substrate. OD₆₅₀ is reported. Background of RAVV rGP Δ muc without positive control serum was **0.062** OD₆₅₀.

Intended for research use only. Not for human, therapeutic, or diagnostic applications.

The buyer cannot sell or otherwise transfer this product for Commercial Purposes without written approval of Integrated BioTherapeutics, Inc.